Market Closed - Euronext Paris 11:35:05 2024-04-25 am EDT 5-day change 1st Jan Change
35.85 EUR +0.99% Intraday chart for Guerbet +9.63% +83.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guerbet: CE certificate for a platform CF
Intrasense: awarded CE certificate CF
Guerbet SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guerbet: results exceed expectations, share price rises CF
Guerbet: two appointments to the executive committee CF
CAC40: gloomy end to the week, timid weekly gain (+0.7%) CF
Guerbet: sales growth of 4% by 2023 CF
Guerbet: positive opinion from the CHMP for Elucirem CF
Guerbet SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guerbet: decline in half-year EBITDA margin CF
Guerbet SA(ENXTPA:GBT) dropped from S&P Global BMI Index CI
Guerbet: back to growth, share price rises CF
Guerbet wins prostate cancer challenge CF
Guerbet: two management appointments CF
Guerbet: agreement on AI for medical imaging CF
Intrasense: joins Guerbet Group following successful takeover bid CF
Guerbet: Intrasense joins the group CF
Guerbet: holds 56.5% of Intrasense following reopening of its offer CF
Guerbet SA completed the acquisition of 17.82% stake in Intrasense SA. CI
Global markets live: Boeing, Google, Meta, Sonos... Our Logo
Guerbet: changes within the Board of Directors CF
Guerbet Announces Management Appointments CI
Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection CI
Guerbet: takeover bid for Intrasense to resume on May 23 CF
Guerbet: successful takeover bid for Intrasense CF
Chart Guerbet
More charts
Guerbet is a European leader in producing and selling contrast products for medical imaging. The group's products make it possible to visualize different organs and the lymphatic and vascular systems of the human body by making them opaque. Net sales break down by product family as follows: - X-ray imaging products (55.4%); - MRI products (32.7%); - other (11.9%): contrast products for echography and nuclear medicine, fine chemicals products. At the end of 2023 the group had 8 production sites located in France (4), the United States (2), Ireland and Brazil. Europe accounts for 39.7% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
35.85 EUR
Average target price
38.63 EUR
Spread / Average Target
+7.76%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. GBT Stock
  4. News Guerbet
  5. Guerbet's Brand Name for Gadopiclenol Gets European Medicines Agency Acceptance